PHRRF (PharmaTher Holdings) Net Change in Cash : $-1.59 Mil (TTM As of Aug. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PharmaTher Holdings Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

PharmaTher Holdings's Net Change in Cash for the three months ended in Aug. 2024 was $-0.24 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Aug. 2024 was $-1.59 Mil.

PharmaTher Holdings Net Change in Cash Historical Data

The historical data trend for PharmaTher Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaTher Holdings Net Change in Cash Chart

PharmaTher Holdings Annual Data

Trend

May21

May22

May23

Net Change in Cash

1.97

4.96

-2.39

PharmaTher Holdings Quarterly Data
	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	Aug24
Net Change in Cash	Get a 7-Day Free Trial											-0.53	-1.23	-0.81	-0.54	-0.24

PharmaTher Holdings Net Change in Cash Calculation

PharmaTher Holdings's Net Change in Cash for the fiscal year that ended in May. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-2.393	+	0	+	0	+	0
	=	-2.39

PharmaTher Holdings's Net Change in Cash for the quarter that ended in Aug. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.243 + 0 + 0 + 0

= -0.24

Net Change in Cash for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaTher Holdings Net Change in Cash Related Terms
Thank you for viewing the detailed overview of PharmaTher Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaTher Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaTher Holdings Ltd (OTCPK:PHRRF) » Definitions » Net Change in Cash

Comparable Companies

XCNQ:COOL XCNQ:MDMA XCNQ:ASEP TSXV:QPT XCNQ:TELI NEOE:BMND TSX:AEZS TSXV:NRX XCNQ:BLAB TSXV:KNE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

PHRM:Canada

Address

82 Richmond Street East, Toronto, ON, CAN, M5C 1P1

Website

https://www.pharmather.com

PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.

PharmaTher Holdings Headlines

From GuruFocus

PharmaTher Announces Update on FDA New Drug Application for Ketamine
By Marketwired • 09-04-2024

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders
By PurpleRose PurpleRose • 07-13-2022

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
By Stock market mentor Stock market mentor • 01-18-2023

PharmaTher Announces Update on FDA New Drug Application for Ketamine
By Marketwired • 11-19-2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
By Marketwired • 04-18-2024

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX� (Ketamine) to the FDA
By Marketwired • 09-06-2023

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX� (Ketamine) for the Treatment of Rett Syndrome
By Stock market mentor Stock market mentor • 02-02-2023

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX� (Ketamine) On-Body Pump System
By Stock market mentor Stock market mentor • 02-07-2023

PharmaTher's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
By Marketwired • 05-15-2024

PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
By Marketwired • 11-13-2024